Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.

Q2 Medicine HIV Clinical Trials Pub Date : 2015-10-01 DOI:10.1179/1945577115Y.0000000004

Lars G Hemkens, Hannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, Danielle Vuichard, Stefan Schandelmaier, Marcel Stöckle, Matthias Briel, Heiner C Bucher

{"title":"Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.","authors":"Lars G Hemkens, Hannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, Danielle Vuichard, Stefan Schandelmaier, Marcel Stöckle, Matthias Briel, Heiner C Bucher","doi":"10.1179/1945577115Y.0000000004","DOIUrl":null,"url":null,"abstract":"Introduction: Benefits and harms of tenofovir disoproxil fumarate (TDF) in HIV-infected, antiretroviral treatment (ART)-naïve patients of any age have not been systematically reviewed since recent milestone trials were published.Methods: We searched MEDLINE, EMBASE, CENTRAL, SCI, LILACS, WHO GHL, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing TDF-based treatments with any other ART-regimen (last search 01/2015). Trial characteristics and results were extracted, risks of bias systematically assessed, and treatment effects synthesized in meta-analyses using random-effects models.Results: We included 22 RCTs (8297 patients). We found no differences between groups for mortality, AIDS, fractures, CD4 cell count, and virological failure; and inconclusive information due to inadequate reporting for cardiovascular events, renal failure, proteinuria, rash, and quality of life. Tenofovir disoproxil fumarate-based regimens significantly reduced total cholesterol (mean difference -18.42 mg/dl; 95% confidence interval [CI] -22.80 to -14.0), LDL-cholesterol (-9.53 mg/dl; -12.16 to -6.89), HDL-cholesterol (-2.97 mg/dl; -4.41 to -1.53), and triglycerides (-29.77 mg/dl; -38.61 to -20.92), bone mineral density (BMD) (hip: -1.41%; -1.87 to -0.94), and glomerular filtration rate (eGFR) (-3.47 ml/minute; -5.89 to -1.06) over 48 weeks of follow-up. Effects were similar in trials comparing fixed-dose TDF/FTC-based regimens with ABC/3TC-based regimens. We found no influence of baseline viral load on virological failure.Discussion: Moderate-quality evidence suggests similar effects of TDF-based treatment regimens and other ART on virological failure. Tenofovir disoproxil fumarate-based regimens are associated with a more favorable lipid profile, but with increased risk of reduced BMD and eGFR. Improved reporting quality is vital to allow assessment of clinical outcomes in future trials.","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1179/1945577115Y.0000000004","citationCount":"23","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1179/1945577115Y.0000000004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 23

Abstract

Introduction: Benefits and harms of tenofovir disoproxil fumarate (TDF) in HIV-infected, antiretroviral treatment (ART)-naïve patients of any age have not been systematically reviewed since recent milestone trials were published.

Methods: We searched MEDLINE, EMBASE, CENTRAL, SCI, LILACS, WHO GHL, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing TDF-based treatments with any other ART-regimen (last search 01/2015). Trial characteristics and results were extracted, risks of bias systematically assessed, and treatment effects synthesized in meta-analyses using random-effects models.

Results: We included 22 RCTs (8297 patients). We found no differences between groups for mortality, AIDS, fractures, CD4 cell count, and virological failure; and inconclusive information due to inadequate reporting for cardiovascular events, renal failure, proteinuria, rash, and quality of life. Tenofovir disoproxil fumarate-based regimens significantly reduced total cholesterol (mean difference -18.42 mg/dl; 95% confidence interval [CI] -22.80 to -14.0), LDL-cholesterol (-9.53 mg/dl; -12.16 to -6.89), HDL-cholesterol (-2.97 mg/dl; -4.41 to -1.53), and triglycerides (-29.77 mg/dl; -38.61 to -20.92), bone mineral density (BMD) (hip: -1.41%; -1.87 to -0.94), and glomerular filtration rate (eGFR) (-3.47 ml/minute; -5.89 to -1.06) over 48 weeks of follow-up. Effects were similar in trials comparing fixed-dose TDF/FTC-based regimens with ABC/3TC-based regimens. We found no influence of baseline viral load on virological failure.

Discussion: Moderate-quality evidence suggests similar effects of TDF-based treatment regimens and other ART on virological failure. Tenofovir disoproxil fumarate-based regimens are associated with a more favorable lipid profile, but with increased risk of reduced BMD and eGFR. Improved reporting quality is vital to allow assessment of clinical outcomes in future trials.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

替诺福韦在treatment-naïve hiv感染患者中的比较疗效:系统评价和荟萃分析。

简介:富马酸替诺福韦二氧吡酯(TDF)对任何年龄的hiv感染抗逆转录病毒治疗(ART)-naïve患者的益处和危害自最近里程碑式试验发表以来尚未进行系统评价。方法:我们检索MEDLINE、EMBASE、CENTRAL、SCI、LILACS、WHO GHL和ClinicalTrials.gov，检索比较tdf治疗与其他art治疗方案的随机对照试验(rct)(上次检索于2015年1月1日)。提取试验特征和结果，系统评估偏倚风险，并在使用随机效应模型的meta分析中综合治疗效果。结果:我们纳入22项随机对照试验(8297例患者)。我们发现两组在死亡率、艾滋病、骨折、CD4细胞计数和病毒学失败方面没有差异;由于对心血管事件、肾衰竭、蛋白尿、皮疹和生活质量的报道不足，信息不确定。以富马酸替诺福韦二氧吡酯为基础的方案显著降低总胆固醇(平均差值-18.42 mg/dl;95%可信区间[CI] -22.80 ~ -14.0)，低密度脂蛋白胆固醇(-9.53 mg/dl;-12.16至-6.89)，高密度脂蛋白胆固醇(-2.97毫克/分升;-4.41至-1.53)，甘油三酯(-29.77 mg/dl;-38.61 ~ -20.92)，骨密度(BMD)(髋部:-1.41%;-1.87 ~ -0.94)，肾小球滤过率(eGFR) (-3.47 ml/分钟;-5.89至-1.06)，随访48周。在比较以固定剂量TDF/ ftc为基础的方案与以ABC/ 3c为基础的方案的试验中，效果相似。我们发现基线病毒载量对病毒学失败没有影响。讨论:中等质量的证据表明，基于tdf的治疗方案和其他抗逆转录病毒治疗方案对病毒学失败的影响相似。以富马酸替诺福韦二氧吡酯为基础的方案与更有利的脂质谱相关，但BMD和eGFR降低的风险增加。提高报告质量对于评估未来试验的临床结果至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

HIV Clinical Trials 医学-传染病学

CiteScore

1.76

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.